Dazolicine

This classification denotes an antiarrhythmic agent with the molecular formula C17H24ClN3S, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier (SRS UNII) 92KE01WH2P, chemically known as 8-chloro-3,4,5,6-tetrahydro-6-((1-isopropyl-2-imidazolin-2-yl)methyl)-2h-1,6-benzothiazocine but more generally known as dazolicine, which bears US NIH Compound Identifier 68810. European Medicines Agency schedules Dazolicine in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB06922MIG. The term DAZOLICINE is an International Non-Proprietary Name or INN (see World Health Organization INN reference publication, Volume 32, No 10 1978, List 18). DAZOLICINE is scheduled in the U.S. International Trade Commission's Harmonized Tariff System (HTS) Pharmaceutical Appendix. Most nations, for tariff and trade purposes, schedule dazolicine under HS 29349990 and SITC 51579. As of Q4 2014, DAZOLICINE remains US FDA's Preferred Term for this commodity. Dazolicine bears US NLM identifiers UMLS ID C0612580 and NCI Concept Code C75128. SMILES: CLC1CC2N(CC3=NCCN3C(C)C)CCCCSC2CC1.